Prof. Dr. Gert N. Moll - CEO and CSO
Gert Moll studied Biology at the University of Utrecht, NL, and did his PhD under the direction of Prof. Dr. L.L.M. van Deenen in Utrecht, and at the CNRS in Montpellier with Dr H.J. Vial. He subsequently worked at the INSERM U251 in Paris, France with Prof. Dr. C. le Grimellec, at the University of Padova in Italy with Prof. C. Montecucco and at the University of Groningen with Prof. Dr. W.N. Konings and Prof. Dr. A.J.M. Driessen. He was member of the Management Team of BioMaDe Technology Foundation, and co-founder and CSO of Lanthio. Since 2015 he is director of Lanthio. He holds a chair as honorary Professor in Protein Modification and Functionality at the University of Groningen.
Annet de Vries - Finance, Admin and HR
Annet had been member of the Management Team of three large regional organizations before entering the Biotech sector as financial head in BioMaDe and thereafter in Lanthio. Annet has large experience in a wide scope of operational and strategic matters including all areas of financial responsibility, controlling and procedures, tax, reporting/due diligence, and forecasting.
Dr. Pawel Namsolleck - Development
Pawel did his undergraduate study at Gdansk University, Poland and worked at the German Institute for Human Nutrition. Thereafter he joined the Center for Cardiovascular Research and the Institute of Pharmacology, Charité – Universitätsmedizin Berlin, where he received his Ph.D. in Pharmacology under supervision of Prof. Thomas Unger, a world-leading expert in protective Renin-Angiotensin System. Subsequently he moved to CARIM – School for Cardiovascular Diseases at the Maastricht University, The Netherlands. Pawel joined Lanthio in 2015 and he coordinates development towards clinical trial application and detailed business analyses. Pawel has large, widely published, experience in animal model studies, safety assessment, pharmacokinetics, pharmacodynamics and MoA studies in many indications including oncology, cardiovascular and metabolic diseases.
The very experienced, dedicated, highly qualified and creative scientific staff, all co-founders of Lanthio, has large expertise in pharmacology, cell biology, molecular biology, microbiology, biochemistry, enzymology, peptide chemistry, analytics and preclinical development. The scientists are the inventors of Lanthio’s IP, developed Lanthio’s proprietary innovative technologies, optimized the application of these technologies, discovered all the lead molecules and performed the in-house part of the preclinical development in Lanthio’s well-equipped laboratories.
Please get in touch if you would like to learn more about Lanthio Pharma.